Novo Nordisk Secures FDA Approval For Higher-Dose Wegovy

Benzinga_recent_news

Mar 20

• Novo Nordisk shares are experiencing downward pressure. What’s pulling NVO shares down? The approval comes via the Commissioner's National Priority Voucher (CNPV) expedited program. The newly ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2620278451"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2620278451\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2620278451?lang=en_US&edition=fundamental","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/03/19/Wegovy.jpeg?optimize=medium&dpr=2&auto=webp&width=240","is_english":true,"pubTime":"2026-03-20 01:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2620278451","market":"sh","top_or_hot":-1,"title":"Novo Nordisk Secures FDA Approval For Higher-Dose Wegovy","media":"Benzinga_recent_news","content":"<div>\n<p>• Novo Nordisk shares are experiencing downward pressure. What’s pulling NVO shares down?\nThe approval comes via the Commissioner's National Priority Voucher (CNPV) expedited program.\nThe newly ...</p>\n\n<a href=\"https://www.benzinga.com/news/fda/26/03/51363862/novo-nordisk-secures-fda-approval-for-higher-dose-wegovy\">Source Link</a>\n\n</div>\n","source":"benzinga_recent_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novo Nordisk Secures FDA Approval For Higher-Dose Wegovy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovo Nordisk Secures FDA Approval For Higher-Dose Wegovy\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-20 01:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/news/fda/26/03/51363862/novo-nordisk-secures-fda-approval-for-higher-dose-wegovy><strong>Benzinga_recent_news</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>• Novo Nordisk shares are experiencing downward pressure. What’s pulling NVO shares down?\nThe approval comes via the Commissioner's National Priority Voucher (CNPV) expedited program.\nThe newly ...</p>\n\n<a href=\"https://www.benzinga.com/news/fda/26/03/51363862/novo-nordisk-secures-fda-approval-for-higher-dose-wegovy\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HMYY","symbol_name":"GraniteShares YieldBoost HIMS ETF","start_time":0,"source_url":"https://www.benzinga.com/news/fda/26/03/51363862/novo-nordisk-secures-fda-approval-for-higher-dose-wegovy","article_id":"2620278451","we_media_id":null,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/03/19/Wegovy.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/fda/26/03/51363862/novo-nordisk-secures-fda-approval-for-higher-dose-wegovy","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2620278451","pubTimestamp":1773942600,"columns":[],"sourceInfo":{"source_id":"benzinga_recent_news","name":"Benzinga"},"weMediaInfo":null,"summary":"FDA approves higher-dose Wegovy to boost weight loss in adults with obesity, with rollout expected across U.S. pharmacies in April.","collect":0,"end_time":0,"defaultTopTitle":"benzinga.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"HMYY":"GraniteShares YieldBoost HIMS ETF","BK4588":"碎股","BK4087":"商业印刷","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","HIMZ":"DEFIANCE DAILY TARGET 2X LONG HIMS ETF","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","BK4007":"制药","BK4196":"保健护理服务","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","HIYY":"YieldMax HIMS Option Income Strategy ETF","BK4599":"减肥药","BK4532":"文艺复兴科技持仓","NVOH":"Novo Nordisk A/S B Shares ADRhedged","NVO":"诺和诺德","NVOX":"2倍做多NVO ETF-Defiance","BK4585":"ETF&股票定投概念","BK4157":"电子设备和仪器","LU0154236417.USD":"BGF US FLEXIBLE EQUITY \"A2\" ACC","HIMY":"Defiance Leveraged Long + Income HIMS ETF","BK4081":"电力公用事业"},"translate_title":"诺和诺德获得FDA批准更高剂量Wegovy","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVO":1.98,"HMYY":0.6,"NVOH":0.6,"HIYY":0.6,"HIMZ":0.6,"NVOX":0.6,"HIMY":0.6},"content_text":"• Novo Nordisk shares are experiencing downward pressure. What’s pulling NVO shares down?\nThe approval comes via the Commissioner's National Priority Voucher (CNPV) expedited program.\nThe newly approved Wegovy HD (semaglutide) injection 7.2 mg is for patients who have already tolerated the currently approved 2.4 mg dose and require additional weight reduction.\nThe therapy is intended to be used alongside a reduced-calorie diet and increased physical activity.\nThe regulatory decision is based on results from the STEP UP clinical program, including a 72-week study evaluating the safety and efficacy of the 7.2 mg dose.\nThe trial enrolled 1,407 adults with obesity, defined as a body mass index (BMI) of 30 kg/m² or higher, without diabetes.\nParticipants receiving the higher dose demonstrated significant weight loss compared to both the placebo and the standard 2.4 mg Wegovy dose.\nJamey Millar, executive vice president of U.S. operations at Novo Nordisk, said the approval reinforces Wegovy's clinical profile.\nHe noted that Wegovy remains the only GLP-1 therapy for obesity proven to reduce the risk of major cardiovascular events — including stroke, heart attack and cardiovascular death — in patients with established heart disease.\nBefore this update, the highest approved Wegovy dose was 2.4 mg, which already carried both weight-loss and cardiovascular risk reduction indications.\nNovo Nordisk said Wegovy HD will be available starting in April across more than 70,000 U.S. pharmacies, including major chains and telehealth platforms.\nPatients will also be able to access the therapy through NovoCare Pharmacy and savings programs aimed at reducing out-of-pocket costs for eligible users.\nOn Wednesday, Hims & Hers Health, Inc. (NYSE:HIMS) said it is collaborating with Novo Nordisk to offer access to the only FDA-approved GLP-1 weight-loss pill, alongside injectable Wegovy in all dosages.\nIt also plans to offer Ozempic injections in all available dosages at cash-pay prices starting at $149 a month.\nIt also launched an \"exclusive pre-launch waitlist\" to give customers priority access to availability updates, transparent pricing, and the debut of the strategic collaboration.\nIn January, the U.K.’s Medicines and Healthcare products Regulatory Agency (MHRA) Wegovy 7.2 mg dose.\nThe European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion for Wegovy 7.2 mg.\nIn the EU, Novo Nordisk expects a regulatory decision in the first quarter of 2026.\nNVO Stock Price Activity: Novo Nordisk shares were down 2.05% at $36.78 at the time of publication on Thursday, according to Benzinga Pro data.\nImage via Shutterstock\nTo add Benzinga News as your preferred source on Google, click here.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}